Company Overview
PAVmed Inc. is a healthcare entity focused on the acquisition, development, and commercialization of novel products designed to address unmet medical needs within the United States market. The company operates specifically within the healthcare sector, specializing in the medical devices industry, which implies a focus on tangible equipment and technologies used in clinical settings. At a scale of 39 employees, the organization maintains a small operational footprint while managing a market capitalization of $7.99M and generating annual revenue of $29,000. These valuation and revenue figures indicate that the company is a micro-cap entity with minimal revenue generation relative to its market valuation, suggesting it is in an early-stage or development-focused phase where market cap reflects potential future value rather than current cash flow production.
Financial Health
The company reported a trailing twelve-month revenue of $29,000 alongside a net income of $-596,000 and an EBITDA of $-20,034,000, revealing a significant disparity between top-line activity and bottom-line profitability. The substantial gap between the low revenue figure and the high net loss indicates a cost structure heavily weighted toward research, development, and operational expenses that have not yet been offset by sales volume. Free cash flow stands at $-11,932,125, which signifies a severe lack of financial flexibility as the company is burning cash rapidly without internal generation to fund operations. All three margin metrics reflect this financial strain, with a gross margin of 0.0%, an operating margin of -96880.0%, and a profit margin of 10672.4%, where the negative operating and profit margins demonstrate that operating expenses vastly exceed both gross revenue and earnings before interest, taxes, depreciation, and amortization. The balance sheet is highly leveraged, holding $3.37M in cash against $9.28M in debt, a disparity that is further contextualized by a debt-to-equity ratio of 35.99. Short-term liquidity is critically constrained, as evidenced by a current ratio of 0.40, which indicates that current liabilities significantly exceed current assets. Return on equity is reported at 17.4% while return on assets is -36.8%, a combination that suggests management is generating equity returns through financial leverage despite the underlying assets contributing negatively to overall profitability.
Valuation Assessment
Valuation multiples for PAVmed Inc. present a complex picture, with a trailing P/E ratio of N/A and a forward P/E of -0.51, implying that the market expects earnings to improve from a loss position in the future, although the negative forward multiple suggests continued earnings contraction or high expectations for a turnaround. The price-to-book ratio is 0.79, indicating that the stock trades at a discount relative to its book value, which typically suggests the market is not pricing in a significant premium for the company's assets. Alternative valuation metrics such as a price-to-sales ratio of 275.43 and an EV/EBITDA of -1.56 suggest that traditional valuation models are difficult to apply due to the lack of profitability and the high multiple applied to minimal sales figures. Price momentum is characterized by a 52-week high of $28.44 and a 52-week low of $6.00, placing the stock's current trading position somewhere within this wide range, reflecting significant price volatility typical of small-cap biotech or device firms. The beta value of 0.88 indicates that the stock's price volatility is slightly lower than the broader market, suggesting it may be less sensitive to general market swings compared to the average equity, though the high valuation multiples and negative earnings still introduce specific sector-related risks.
Growth & Income
Growth metrics show a revenue growth rate of -99.5% year-over-year and an earnings growth rate of N/A, indicating that the company is currently contracting in terms of top-line revenue and has no reported earnings history to compare against. Since the earnings growth rate is not available due to the lack of prior earnings, the relationship between earnings and revenue cannot be directly compared, but the negative revenue growth implies a decline in sales or a shift in business operations. As a non-dividend payer with a dividend yield of N/A and a payout ratio of 0.0%, the company does not distribute cash to shareholders, meaning any retained earnings are reinvested into growth initiatives or used to service debt rather than providing current income. The overall growth and income profile is defined by significant revenue contraction and a complete absence of dividend income, characteristic of a development-stage company that prioritizes capital expenditure over shareholder returns.